Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
Status:
Terminated
Trial end date:
2021-05-04
Target enrollment:
Participant gender:
Summary
The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel
coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19
patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed
ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various
effects on the immune system and several diseases, including lung diseases. This trial aims
to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of
COVID-19. The trial will be randomized without blinding, with one are treated by insulin only
for glucose balance and the other by insulin and linagliptin. The trial will assess the
effects of linagliptin on different measures of COVID-19 recovery.